Duffy Sean P. sold $342K of OMDA

Duffy Sean P. (Chief Executive Officer) sold 17,258 shares of Omada Health, Inc. (OMDA) at an average of $19.82 ($19.00–$20.90, $0.34M total) across 4 trades over 2026-06-24 to 2026-06-26 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Duffy Sean P.
Published Jun 26, 2026, 11:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 26, 2026, 11:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$OMDA
Neutral
high confidence
Mentioned
$OMDA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OMDANeutralLow
01

Why it matters

The CEO’s open-market sale totals ~$342K across 17,258 shares at prices ranging from ~$19.00 to ~$20.90, with a stated pre-arranged 10b5-1 plan.

02

Market read

This is a routine insider-selling disclosure; it may marginally influence sentiment but lacks new fundamental information.

03

What to watch

The filing doesn’t disclose any change in business outlook, guidance, or risk factors—so traders should avoid over-weighting it versus fundamentals.

Relevance 3/10Novelty 3/10Timing: Filed 2026-06-26 after trades dated 2026-06-24 to 2026-06-26

Background

The article is a primary-source SEC Form 4 insider transaction for Omada Health, Inc. (OMDA).

Company-level read

Ticker impact

$OMDANeutralHigh confidence
Context

Omada Health CEO Sean Duffy sold $342.1K of OMDA shares in four trades under a pre-arranged 10b5-1 plan (6/24–6/26).

Expected impact

Low likelihood of a sustained price move solely from this Form 4 sale; any reaction is likely muted and short-lived.

Evidence & confidence

The disclosure is an open-market sale by the CEO with an explicitly pre-arranged 10b5-1 plan, and the article contains no new operational, financial, or regulatory developments.

Market effects

No direct sector read-through; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

Because it’s a 10b5-1 plan, the sale may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • Omada Health, Inc.

    Issuer of the Form 4 insider transaction; CEO Sean Duffy sold shares under a 10b5-1 plan.

  • Sean P. Duffy

    Chief Executive Officer and officer/director who executed the open-market sales.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$OMDAHigh

Omada Health Earnings Call Signals Strong Growth Ahead

Omada Health (OMDA) reported Q3 revenue of $91M, up 34% YoY, with GAAP net income of $7M vs. a loss last year. Adjusted EBITDA rose to $12M. Management raised 2026 revenue guidance to $344M-$346M and adjusted EBITDA to $32M-$34M, citing strong demand for diabetes and hypertension programs. The company expects Q4 seasonality and GLP-1 coverage uncertainty.

$OMDAMed

What Omada Health (OMDA) Said on Its Q3 Earnings Call

Omada Health (OMDA) expects Q4 revenue to decline due to seasonal factors, with adjusted EBITDA also moderating. The company ended Q3 with $243M in cash and no debt. CEO Sean Duffy will transition to executive chair in 2027, with Shao taking over as CEO. Omada's GLP-1 Care Track showed a 6% average weight loss at 12 weeks, according to peer-reviewed research.

$OMDAMedAI 8/10

Omada Health Inc (OMDA) (Q3 2026) Earnings Call Highlights: Record Revenue, Membership

Omada Health Inc (OMDA) reported record revenue and membership growth in Q3 2026. However, new enrollments are expected to decline in Q4 due to seasonality and tough comparisons. GLP-1 market dynamics and rising healthcare costs create uncertainty for 2027. Adjusted EBITDA is expected to moderate due to increased R&D and staffing. The company aims for 20%+ growth in 2027 through expanding covered lives, improving enrollment rates, and increasing engagement.